Wave Life Sciences (WVE) saw its loss widen to $21 million, or $0.89 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $7.85 million, or $0.36 a share. Revenues for the quarter were $0.68 million. The company has not recorded any revenues for the previous year period.
Operating loss for the quarter was $19.91 million, compared with an operating loss of $7.95 million in the previous year period.
"The beginning of 2017 was marked by continued advancement of our lead programs in HD and DMD and substantial progress in our collaboration with Pfizer. Our two HD programs and our DMD program remain on track to enter the clinic in 2017, and we will announce our next three pipeline candidates later this year," said Paul Bolno, M.D., MBA, president and chief executive officer of WAVE Life Sciences. "We have also made significant advancements within our discovery platform, deepening our knowledge and capabilities in both existing (antisense and exon skipping) and new (ssRNAi and splicing) modalities, and we are exploring new approaches to identify and target specific cell populations as we look ahead to our next set of pipeline candidates."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
